| Date | Title | Description |
| 11.07.2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| 10.07.2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank.
Current investors included SV Health Investors and the Dementia Discovery Fun... |
| 12.05.2026 | Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 | Boston – MAY 12, 2026 – Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evalu... |
| 10.01.2026 | UPenn, BioNTech, And Osage University Partners Launch $50 Million Seed Fund To Back Penn Life Science Startups | The University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a dedicated venture fund focused on early-stage life scienc... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 30.09.2025 | Crystalys Therapeutics Raises in $205M Series A Funding | Crystalys Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company, raised $205M in Series A funding.
The round was led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors,... |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 09.09.2025 | Alchemab Therapeutics Raises Series A Extension Financing | Alchemab Therapeutics, a London, UK-based biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, raised an undisclosed amount in Series A extension funding.
Backers inc... |
| 02.09.2025 | ProVerum: $80 Million Series B Raised For Advancing BPH Treatments | ProVerum Limited is a company that has made significant strides with its development of the ProVee System, a minimally invasive solution specifically designed for treating benign prostatic hyperplasia (BPH). Recently, the company announced ... |
| 27.08.2025 | Reprieve Cardiovascular Raises $61M in Series B Financing | Reprieve Cardiovascular, a Milford, MA-based clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), raised $61M in Series B funding.
The round was led by Deerfield Managem... |
| 26.08.2025 | Irish MedTech startup ProVerum raises €68.6 million to advance new treatment for urological conditions | ProVerum, a MedTech startup based in Dublin, has secured €68.6 million in Series B equity financing to advance the commercialisation of its minimally invasive solution for benign prostatic hyperplasia (BPH).
The round was led by MVM Partner... |
| 13.08.2025 | Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study | — Series B fundraise led by Deerfield Management enables scaling of pivotal clinical trial and commercial readiness activities for Reprieve® System
– First patient enrolled in FASTR II study by Washington University School of Medicine in St... |
| 13.08.2025 | Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure Trial | What You Should Know:
– Reprieve Cardiovascular, a clinical-stage company secures $61M in Series B funding led by Deerfield Management and included participation from several other investors, such as Arboretum Ventures, Lightstone Ventures,... |
| 09.08.2025 | Apreo Health Secures $130M to Revolutionize Emphysema Care | Apreo Health secured $130 million in Series B funding. This major investment propels its BREATHE Airway Scaffold, an innovative medical device for severe emphysema. The scaffold addresses lung hyperinflation, aiming to redefine treatment fo... |
| 08.08.2025 | Apreo Health: $130 Million Series B Raised For Developing Treatments For Severe Emphysema | Apreo Health, a clinical-stage medical device company focused on innovative treatments for severe emphysema, has announced the successful completion of an oversubscribed $130 million Series B financing round. This funding was jointly led by... |
| 07.08.2025 | Apreo Health Closes $130M in Series B Financing | Apreo Health, a Menlo Park, CA-based clinical-stage medical device company developing a novel treatment for severe emphysema, raised $130M in Series B funding.
The round was led by Bain Capital Life Sciences and Norwest, with participation ... |
| 08.01.2025 | FIRE1 Secures $120M for Heart Failure Management Platform | What You Should Know:
– FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner... |
| 23.02.2024 | Reprieve Cardiovascular Revolutionizes Heart Failure Treatment with $42M Funding | Reprieve Cardiovascular, a Milford, MA-based company, secures $42M in Series A funding to advance intelligent fluid management for heart failure patients. Led by Lightstone Ventures and Sante Ventures, the funding will propel Reprieve's mis... |
| 22.02.2024 | Reprieve Cardiovascular Nabs $42M to Expand Intelligent Fluid Management for Heart Failure | What You Should Know:
– Reprieve Cardiovascular, a pioneer in personalized fluid management for acute decompensated heart failure (ADHF) emerges from stealth launching with $42M in Series A financing round.
– The Series A round was co-led b... |
| 26.06.2023 | Dutch-based Tagworks Pharmaceuticals raises €59.5M to design effective, safe systemic therapies | The Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Release chemistry to deliver effective and safer systemic therapies, announced on Thursday, June 22, that it has raised $65M (approximately €5... |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build.
ClavystBio has committed US$220 million to date in investments to launch global ... |
| 14.09.2021 | Lightstone Ventures Raises $375 Million Fund | - |
| 14.09.2021 | After 3 big exits, Lightstone snags largest fund yet with $375M geared toward next biotechs, medtechs
How to Optimize In Vitro and In Vivo Data Analysis and Data Management in Drug Research | After seeing Ra Pharmaceuticals, Disarm Therapeutics and Tizona Therapeutics to exits last year, Lightstone Ventures is back with $375 million to plant a seed in early-stage biotech and medtech startups.
Lightstone's raise comes amid a bann... |
| 14.09.2021 | A not-so-secret, secret ingredient in Mailchimp’s new $12 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content How data can accelerate growth and innovation From Deloitte
In a year when unicorn s... |
| 14.09.2021 | Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech and Medtech Companies | What You Should Know:
– Lightstone Ventures today announced the closing of Lightstone Ventures III with $375M in capital commitments, to invest in early-stage companies developing high-impact therapeutics and technologies.
– The new fund wa... |
| 14.09.2021 | Lightstone Ventures’ raises $375M for its largest fund yet | - |
| 14.09.2021 | A not-so-secret, secret ingredient in Mailchimp’s new $12 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content How to ensure your marketers stay dynamic and agile From Optimizely
In a year when u... |
| 14.09.2021 | Lightstone Ventures : Raises $375 Million Fund | MENLO PARK, Calif. and BOSTON, Sept. 14, 2021 /PRNewswire/ -- Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact the... |
| 05.02.2020 | Lightstone Completes $103 Million Series B | Lightstone has completed a Series B bond offering of $103 million on the Tel Aviv Stock Exchange.
The bonds were sold by Lightstone Enterprises Limited (LEI), a BVI-registered public company that is a wholly-owned entity of Lightstone. The ... |
| 18.10.2017 | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, according to a news release. They also took part in the seed round last year.
James McLaughlin, Gemini Therapeutics cofounder and CEO, said that the company focuses on pati... |
| 22.09.2017 | Venture Capital Firm Lightstone Ventures Raises $250M for Third Fund | Lightstone Ventures, a Boston, Menlo Park, Dublin, and Singapore-based global venture capital firm, raised $250m for Lightstone Ventures II, L.P. (LSV II).
With LSV II, an over-subscribed fund that exceeded its target of $200 million, Light... |
| 20.09.2017 | Lightstone Ventures Closes New Life Sciences Fund at $250 Million | - |
| 20.09.2017 | Lightstone Ventures Closes New Life Sciences Fund at $250 Million | MENLO PARK, Calif. and BOSTON, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lightstone Ventures (LSV), a leading global venture capital firm, today announced it has raised $250 million for Lightstone Ventures II, L.P. (LSV II). The firm also announce... |
| 06.12.2016 | Cerevance Raises $36M Funding from Lightstone Ventures | OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) and Lightstone Ventures today announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel the... |
| 13.09.2016 | Lightstone Ventures Adds Susan M. Molineaux as Scientific Advisor | Lightstone Ventures has appointed Susan M. Molineaux, Ph.D. as Scientific Advisor.
In this role, she will assist the LSV biotechnology team with deal sourcing and due diligence.
Dr. Molineaux also continues to serve as the President, Chief ... |
| 18.02.2016 | Lightstone Ventures Closes US$50M Venture Capital Fund | Global venture capital firm Lightstone Ventures (LSV) closed a US$50m fund focused on investing in Singapore-based life sciences companies.
Limited Partners in Lightstone Singapore, L.P., include Temasek, an investment company based in Sing... |
| 18.02.2016 | Experienced med tech investor Lightstone Ventures closes $50M Singapore fund | - |
| 17.02.2016 | Lightstone Ventures closes $50m Singapore-focussed fund. Temasek, EDBI among investors | Premium
US-based lifesciences fund Lightstone Ventures (LSV), has closed a $50-million Singapore-focussed fund with investments from the corporate investment arm of the Singapore Economic Development Board – EDBI, and the state investment f... |
| 16.02.2016 | Stealth Stanford spinout Cala Health raises $18M for wearable device that treats hand and wrist tremors | Cala Health was founded two years ago by Stanford Biodesign 2012 fellow Kate Rosenbluth. However, in 2013 she won a $10,000 “Boomer” award for another company, Resido Medical, that is meant to treat essential tremor – a condition prevalent ... |
| 24.07.2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M
AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| 02.05.2014 | Lightstone Ventures Closes Life Sciences VC Fund at $172M | Life Sciences vc firm Lightstone Ventures (LSV) closed its first fund at $172m.
Lightstone Ventures, L.P., targets investment opportunities in early-stage biotechnology and medical device companies.
The fund has already made three investmen... |
| 01.05.2014 | Morgenthaler, ATV vets team up for new $172M early-stage life science venture capital fund | Carusi said in a statement that a lively IPO market, improvements at the FDA and interest from large corporate players to invest in and acquire life science companies has created a lot of promise in the sector, making it appealing for inves... |
| 01.05.2014 | VC Lightstone lands $172M fund with an eye on biotech startups | - |
| 09.01.2014 | FIRE1 Raises Series A Funding | FIRE1, a Dublin, Ireland-based developer of novel therapeutic devices, raised a Series A funding of undisclosed amount.
The company is incubated within The Foundry, a medical device incubator.
Backers included Covidien plc (NYSE: COV), Ligh... |
| - | Stealth Stanford spinout Cala Health raises $18M for wearable device that treats hand and wrist tremors | Stealth Bay Area medical device maker Cala Health looks to have closed out an $18 million Series A round, according to a regulatory filing. Investors in the company include Johnson & Johnson Development Corporation, Lux Capital and Ligh... |
| - | Morgenthaler, ATV vets team up for new $172M early-stage life science venture capital fund | Four general partners from Advanced Technology Ventures‘ and Morgenthaler Ventures‘ life science teams have joined forces to invest up to $172 million in biopharmaceutical and medical device startups.
Lightstone Ventures, led by Michael Car... |
| - | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Fundus photo of macular scarring with normal blood vessels and optic nerve
Gemini Therapeutics has closed a Series A round to advance its precision medicine therapy for dry age-related macular degeneration. The Cambridge, Massachusetts comp... |
